Связь полиморфизмов гена CYP2C19 и клинических исходов у пациентов с инфарктом миокарда в течение 60 месяцев наблюдения

Связь полиморфизмов гена CYP2C19 и клинических исходов у пациентов с инфарктом миокарда в течение 60 месяцев наблюдения

Автор: Гражданкин И.О., Прохорихин А.А., Байструков В.И., Кретов Е.И., Чернявский А.М., Лукинов В.Л.

Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin

Рубрика: Патологическая физиология

Статья в выпуске: 4 т.27, 2023 года.

Бесплатный доступ

Цель. Оценить взаимосвязь полиморфизмов гена CYP2C19 и клинических исходов у пациентов после успешной реваскуляризации по поводу острого инфаркта миокарда с подъемом и без подъема сегмента ST на фоне терапии клопидогрелом на протяжении 60 мес. наблюдения.

Клопидогрел, острый коронарный синдром, полиморфизм cyp2c19, предиктор неблагоприятного исхода, реваскуляризация миокарда

Короткий адрес: https://sciup.org/142240113

IDR: 142240113   |   DOI: 10.21688/1681-3472-2023-4-64-76

Список литературы Связь полиморфизмов гена CYP2C19 и клинических исходов у пациентов с инфарктом миокарда в течение 60 месяцев наблюдения

  • Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Barengo N.C., Beaton A.Z., Benjamin E.J., Benziger C.P., Bonny A., Brauer M., Brodmann M., Cahill T.J., Carapetis J., Catapano A.L., Chugh S.S., Cooper L.T., Coresh J., Criqui M., DeCleene N., Eagle K.A., Emmons-Bell S., Feigin V.L., Fernandez-Solà J., Fowkes G., Gakidou E., Grundy S.M., He F.J., Howard G., Hu F., Inker L., Karthikeyan G., Kassebaum N., Koroshetz W., Lavie C., Lloyd-Jones D., Luivi H.S., Mirijello A., Temesgen A.M., Mokdad A., Moran A.E., Muntner P., Narula J., Neal B., Ntsekhe M., Moraes de Oliveira G., Otto C., Owolabi M., Pratt M., Rajagopalan S., Reitsma M., Ribeiro A.L.P., Rigotti N., Rodgers A., Sable C., Shakil S., Sliwa-Hahnle K., Stark B., Sundstrom J., Timpel P., Tleyjeh I.M., Valgimigli M., Vos T., Whelton P.K., Yacoub M., Zuhlke L., Murray C., Fuster V.; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. PMID: 33309175; PMCID: PMC7755038. https://doi. org/10.1016/j.jacc.2020.11.010
  • Collet J.-P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L., Dendale P., Dorobantu M., Edvardsen T., Folliguet T., Gale C.P., Gilard M., Jobs A., Juni P., Lambrinou E., Lewis B.S., Mehilli J., Meliga E., Merkely B., Mueller C., Roffi M., Rutten F.H., Sibbing D., Siontis G.C.M.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 ;42(14):1289-1367. Erratum in: Eur Heart J. 2021;42(19):1908. Erratum in: Eur Heart J. 2021;42(19):1925. Erratum in: Eur Heart J. 2021;42(23):2298. PMID: 32860058. https://doi.org/10.1093/ eurheartj/ehaa575
  • Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A., Juni P., Kastrati A., Kolh P., Mauri L., Montalescot G., Neumann F.-J., Petricevic M., Roffi M., Steg P.G., Windecker S., Zamorano J.L., Levine G.N.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. PMID: 28886622. https://doi.org/10.1093/eurheartj/ehx419
  • Shuldiner A.R., O'Connell J.R., Bliden K.P., Gandhi A., Ryan K., Horenstein R.B., Damcott C.M., Pakyz R., Tantry U.S., Gibson Q., Pollin T.I., Post W., Parsa A., Mitchell B.D., Faraday N., Herzog W., Gurbel P.A. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857. PMID: 19706858; PMCID: PMC3641569. https://doi.org/10.1001/jama.2009.1232
  • Зеленская Е.М., Барбараш О.Л., Ганюков В.И., Кочергин Н.А., Апарцин К.А., Горохова А.В., Папешина С.А., Николаев К.Ю., Батуева К.Ю., Янковская С.В., Тронин А.В., Лифшиц Г.И. Протокол: влияние сочетанного носительства СУР2С19*2 и *17 на эффективность лечения клопидогрелом. Российский кардиологический журнал. 2017;( 10):113-117. https://doi. org/10.15829/1560-4071-2017-10-113-117; Zelenskaya Е.М., Barbarash O.L., Ganyukov V.I., Kochergin N.A., Apartsin КА, Gorokhova A.V., Papeshina S.A., Nikolaev ^Yu., Batueva ^Yu., Yankovskaya S.V., Tronin A.V., Lifshits G.I. The protocol: influence of the combination carriage СУР2С19*2 and *17 on efficacy of clopidogrel. Russian Journal of Cardiology. 2017;(10):113-117. (In Russ.) https://doi. org/10.15829/1560-4071-2017-10-113-117
  • Mega J.L., Close S.L., Wiviott S.D., Shen L., Walker J.R., Simon T., Antman E.M., Braunwald E., Sabatine M.S. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312-1319. PMID: 20801494; PMCID: PMC3036672. https://doi. org/10.1016/S0140-6736(10)61273-1
  • Collet J.-P., Hulot J.-S., Pena A., Villard E., Esteve J.-B., Silvain J., Payot L., Brugier D., Cayla G., Beygui F., Bensimon G., Funck-Brentano C., Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317. PMID: 19108880. https://doi. org/10.1016/S0140-6736(08)61845-0
  • Price M.J., Berger P.B., Teirstein P.S., Tanguay J.-F., Angiolillo D.J., Spriggs D., Puri S., Robbins M., Garratt K.N., Bertrand O.F., Stillabower M.E., Aragon J.R., Kandzari D.E., Stinis C.T., Lee M.S., Manoukian S.V., Cannon C.P., Schork N.J., Topol E.J.; GRAVITAS Investigators. Standard- vs highdose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-1105. Erratum in: JAMA. 2011;305(21):2174. Stillablower, Michael E. [corrected to Stillabower, Michael E.]. PMID: 21406646. https://doi. org/10.1001/jama.2011.290
  • Cavallari L.H., Lee C.R., Beitelshees A.L., Cooper-DeHoff R.M., Duarte J.D., Voora D., Kimmel S.E., McDonough C.W., Gong Y., Dave C.V., Pratt V.M., Alestock T.D., Anderson R.D., Alsip J., Ardati A.K., Brott B.C., Brown L., Chumnumwat S., Clare-Salzler M.J., Coons J.C., Denny J.C., Dillon C., Elsey A.R., Ha-madeh I.S., Harada S., Hillegass W.B., Hines L., Horenstein R.B., Howell L.A., Jeng L.J.B., Kelemen M.D., Lee Y.M., Magvanjav O., Montasser M., Nelson D.R., Nutescu E.A., Nwaba D.C., Pakyz R.E., Palmer K., Peterson J.F., Pollin T.I., Quinn A.H., Robinson S.W., Schub J., Skaar T.C., Smith D.M., Sriramoju V.B., Starostik P., Stys T.P., Stevenson J.M., Varunok N., Vesely M.R., Wake D.T., Weck K.E., Weitzel K.W., Wilke R.A., Willig J., Zhao R.Y., Kreutz R.P., Stouffer G.A., Empey P.E., Limdi N.A., Shuldiner A.R., Winterstein A.G., Johnson J.A.; IGNITE Network. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACCCardiovasc Interv. 2018;11(2):181-191. PMID: 29102571; PMCID: PMC5775044. https://doi. org/10.1016/j.jcin.2017.07.022
  • Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006;8(1):E101-E111. PMID: 16584116; PMCID: PMC2751428. https://doi.org/10.1208/ aapsj080112
  • Гражданкин И.О., Байструков В.И., Кретов Е.И., Прохорихин А.А., Чернявский А.М. Влияние полиморфизмов гена CYP2C19 на клинические исходы пациентов с инфарктом миокарда в течение 12-месячного периода наблюдения. Комплексные проблемы сердечно-сосудистых заболеваний. 2022;11 (3):17-28. https://doi.org/10.17802/2306-1278-2022-11-3-17-28; Grazhdankin I.O., Baystrukov V.I., Kretov E.I., Prokhorikhin A.A., Chernyavsky A.M. Impact of CYP2C19 gene polymorphisms on clinical outcomes in patients with myocardial infarction during 12-month follow-up. Complex Issues of Cardiovascular Diseases. 2022;11 (3):17-28. (In Russ.) https://doi.org/10.17802/2306-1278-2022-11-3-17-28
  • Patel A., Goodman S.G., Tan M., Suskin N., McKelvie R., Mathew A.L., Lutchmedial S., Dehghani P., Lavoie A.J., Huynh T., Lavi S., Philipp R., Khan R., Yan A.T., Radhakrishnan S., Sedlak T., Brunner N., Kim H.H., Cieza T., Kassam S., Fordyce C.B., Heffernan M., Jedrzkiewicz S., Madan M., Ahmed S., Barry C., Dery J.-P., Bagai A.; Canadian ACS Reflective II Investigators. Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. Clin Cardiol. 2021;44(6):839-847. PMID: 33982795; PMCID: PMC8207978. https://doi.org/10.1002/clc.23618
  • Karve A.M., Seth M., Sharma M., LaLonde T., Dixon S., Wohns D., Gurm H.S. Contemporary use of ticagrelor in interventional practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol. 2015;115(11):1502-1506. PMID: 25846767. https://doi.org/10.1016/j. amjcard.2015.02.049
  • Lee C.R., Luzum J.A., Sangkuhl K., Gammal R.S., Sabatine M.S., Stein C.M., Kisor D.F., Limdi N.A., Lee Y.M., Scott S.A., Hulot J.-S., Roden D.M., Gaedigk A., Caudle K.E., Klein T.E., Johnson J.A., Shuldiner A.R. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959-967. PMID: 35034351; PMCID: PMC9287492. https://doi. org/10.1002/cpt.2526
  • Holmes M.V., Perel P., Shah T., Hingorani A.D., Casas J.P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2704-2714. PMID: 22203539. https://doi. org/10.1001/jama.2011.1880
  • FDA drug safety communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. March 8, 2017. Available from: https://www.fda. gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor
  • Trenk D., Hochholzer W., Fromm M.F., Chialda L.-E., Pahl A., Valina C.M., Stratz C., Schmiebusch P., Bestehorn H.-P., Buttner H.J., Neumann F.-J. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-1934. PMID: 18482659. https://doi.org/10.1016/j.jacc.2007.12.056
  • Zhang Y.-J., Li D.-J., Li Z.-Y., Hu X.-L., Li H., Ma Q.-L., Chen X.-P. Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. BMC Cardiovasc Disord. 2022;22(1):575. PMID: 36581799; PMCID: PMC9801627. https://doi.org/10.1186/ s12872-022-02988-w
  • Olie R.H., Hensgens R.R.K., Wijnen P.A.H.M., Veenstra L.F., de Greef B.T.A., Vries M.J.A., van der Meijden P.E.J., Ten Berg J.M., Ten Cate H., Bekers O., Henskens Y.M.C. Differential impact of cytochrome 2C19 allelic variants on three different platelet function tests in clopidogrel-treated patients. J Clin Med. 2021;10(17):3992. PMID: 34501440; PMCID: PMC8432532. https://doi.org/10.3390/jcm10173992
  • Bhatt D.L., Simonsen K.L., Emison E.S., on behalf of the CHARISMA Executive Committee and Investigators. CHARISMA genomics. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009 Meeting; Sept. 30, 2009; San Francisco, California.
  • Dahabreh I.J., Moorthy D., Lamont J.L., Chen M.L., Kent D.M., Lau J. Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment. Comparative Effectiveness Reviews. No. 125. Rockville: Agency for Healthcare Research and Quality (US); 2013. Report No.: 13-EHC117-EF. PMID: 25165804. Available from: https://www.ncbi.nlm.nih.gov/ sites/books/NBK236984
  • Bertrand-Thiebault C., Berrahmoune H., Thompson A., Marie B., Droesch S., Siest G., Foernzler D., Visvikis-Siest S. Genetic polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation. Ann Hum Genet. 2008;72(Pt 2):178-183. PMID: 18205890. https://doi.org/10.1111/M469-1809.2007.00417.x
  • Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W.L., Braunwald E., Sabatine M.S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553-2560. PMID: 19414633. https://doi. org/10.1161/CIRCULATIQNAHA.109.851949
  • Wallentin L., James S., Storey R.F., Armstrong M., Barratt B.J., Horrow J., Husted S., Katus H., Steg P.G., Shah S.H., Becker R.C.; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320-1328. PMID: 20801498. https://doi. org/10.1016/S0140-6736(10)61274-3
  • Mehta S.R., Tanguay J.-F., Eikelboom J.W., Jolly S.S., Joyner C.D., Granger C.B., Faxon D.P., Rupprecht H.-J., Budaj A., Avezum A., Widimsky P., Steg P.G., Bassand J.-P., Montalescot G., Macaya C., Di Pasquale G., Niemela K., Ajani A.E.,White H.D., Chrolavicius S., Gao P., Fox K.A., Yusuf S.; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-1243. PMID: 20817281. https:// doi.org/10.1016/S0140-6736(10)61088-4
  • von Beckerath N., Taubert D., Pogatsa-Murray G., Schömig E., Kastrati A., Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112(19):2946-2950. PMID: 16260639. https:// doi.org/10.1161/CIRCULATI0NAHA.105.559088
  • Montalescot G., Sideris G., Meuleman C., Bal-dit-Sollier C., Lellouche N., Steg P.G., Slama M., Milleron O., Collet J.-P., Henry P., Beygui F., Drouet L.; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48(5):931-938. PMID: 16949482. https://doi.org/10.1016/uacc.2006.04.090
  • Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111(16):2099-2106. PMID: 15750189. https:// doi.org/10.1161/01.CIR.0000161383.06692.D4
  • Zhang L., Yang J., Zhu X., Wang X., Peng L., Li X., Cheng P., Yin T. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention — a systematic review and meta-analysis. Thromb Res. 2015;135(3):449-458. PMID: 25511576. https:// doi.org/10.1016/i.thromres.2014.12.007
  • Thomas M.R., Storey R.F. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. J Cardiovasc Transl Res. 2014;7(1):19-28. PMID: 24309957. https://doi.org/10.1007/s12265-013-9524-6
Еще
Статья научная
SciUp 2024 © 2024 ©